782 related articles for article (PubMed ID: 17218848)
41. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?
van Altena AM; Holtsema H; Hendriks JC; Massuger LF; de Hullu JA
Menopause; 2011 Feb; 18(2):133-7. PubMed ID: 20861755
[TBL] [Abstract][Full Text] [Related]
42. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
Haldar K; Crawford R
Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
[No Abstract] [Full Text] [Related]
43. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
44. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
[TBL] [Abstract][Full Text] [Related]
45. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
[TBL] [Abstract][Full Text] [Related]
46. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy.
ACOG
Obstet Gynecol; 2008 Jan; 111(1):231-41. PubMed ID: 18165419
[No Abstract] [Full Text] [Related]
47. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
McEwen AR; McConnell DT; Kenwright DN; Gaskell DJ; Cherry A; Kidd AM
Gynecol Oncol; 2004 Mar; 92(3):992-4. PubMed ID: 14984974
[TBL] [Abstract][Full Text] [Related]
48. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
49. Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.
Escobar PF; Starks DC; Fader AN; Barber M; Rojas-Espalliat L
Gynecol Oncol; 2010 Oct; 119(1):43-7. PubMed ID: 20579712
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Mahajan NN
Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
[No Abstract] [Full Text] [Related]
51. [Familial history of ovarian carcinoma: policy].
de Hullu JA; Kets CM; Massuger LF; Ligtenberg ML; van Ham MA; Hoogerbrugge N
Ned Tijdschr Geneeskd; 2011; 155():A2392. PubMed ID: 21262027
[TBL] [Abstract][Full Text] [Related]
52. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
Michelsen TM; Dørum A; Dahl AA
Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
[TBL] [Abstract][Full Text] [Related]
53. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families.
Chen LM; Yang KY; Little SE; Cheung MK; Caughey AB
Obstet Gynecol; 2007 Jul; 110(1):18-25. PubMed ID: 17601891
[TBL] [Abstract][Full Text] [Related]
54. Malignancies following bilateral salpingo-oophorectomy (BSO).
Gotlieb WH; Barchana M; Ben-Baruch G; Friedman E
Eur J Surg Oncol; 2006 Dec; 32(10):1231-4. PubMed ID: 16626923
[TBL] [Abstract][Full Text] [Related]
55. Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
Marchetti C; Iadarola R; Palaia I; di Donato V; Perniola G; Muzii L; Panici PB
Menopause; 2014 Jul; 21(7):763-8. PubMed ID: 24253485
[TBL] [Abstract][Full Text] [Related]
56. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
[TBL] [Abstract][Full Text] [Related]
57. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
[No Abstract] [Full Text] [Related]
58. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
59. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
[TBL] [Abstract][Full Text] [Related]
60. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Powell CB
Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
